Pharmaceutical companies under Baiyunshan have been notified and have been "pull -ups" in many places before.

On the 9th, the National Medical Insurance Bureau issued a notice saying that Baiyunshan Pharmaceutical's subsidiary Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (hereinafter referred to as Tianxin Pharmaceutical), Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Three companies including Guangzhou Baiyunshan Jingxiu Pharmaceutical Co., Ltd. (hereinafter referred to as Jingxiutang Pharmaceuticals) have the cases of drug deficiency and high pricing and collection of funds.

Baiyunshan Pharmaceutical response

On the 10th, Baiyunshan Pharmaceutical issued an announcement, stating that it was learned that the report issued by the National Medical Security Bureau's website and had taken a series of rectification measures.

"The company has instructed the cooperation with the Baiyunshan Pharmaceutical General Plant, Tianxin Pharmaceutical and Jingxiu House Pharmaceuticals with relevant agents and dealers to comprehensively rectify the marketing model, and conduct relevant products to reduce prices or withdraw from the Internet across the country. Do not protect it, resolutely handle it, and have been exempted or suspended to the relevant person in charge of the three companies. "Bai Yunshan Pharmaceutical wrote in the announcement.

At the same time, Baiyunshan Pharmaceuticals estimated that the three companies involved the withdrawal of the network products said that it was expected to have a certain impact on the company's future product sales in the future, but it would not have a significant impact on the company's operating performance.

"After investigation, in 2021, the total gross profit of the above three companies involved the total gross profit of the withdrawal of the network was RMB 1.15 million, and the gross profit reduction of prices was RMB 320 million, accounting for the company's 2021 -audited gross profit ratio of 0.12%and 2.45%, respectively. ; From January to March 2022, the above three companies involved the gross profit of the withdrawal of the net products was RMB 1.12 million, and the gross profit reduction of prices was RMB 102 million, accounting for the company's unveiled gross profit amount from January to March 2022, 2022. 0.25%and 2.13%, respectively. "Bai Yunshan Medicine wrote.

False price Purchasing APR

According to the State Medical Insurance Bureau, from May 2017 to May 2021, three pharmaceutical manufacturers including Tianxin Pharmaceuticals in order to avoid the "two -vote system" policies and supervision, and they colluded with more than 50 pharmaceutical agents in the lower reaches, and The 87 kinds of drugs were cash out by the way to purchase raw medicines in virtual high -priced prices, and transferred funds to downstream drug agents. The amount involves huge amounts, and some of them are used for bribery medical staff or specific relationship persons to carry out drug violations.

In terms of cash out, pharmaceutical manufacturers signed a cooperation agreement with the drug agent to add the designated "dealer" in the procurement of the raw and drug, and "dealers" in a low purchase and sell Ten times are sold to drug manufacturers. Pharmaceutical manufacturers will be further transmitted to the price of factory and bidding networks according to the price price of virtual high -level raw drugs.

"Taking cephalosporin as an example, Baiyunshan Pharmaceutical (Preparation Factory) and Baiyunshan Chemical Pharmaceutical Factory (raw material factory) belong to the same group. However Instead, the additional cash process is set up, and the agent controlled by the agent's "dealer 'to turn to hand, buy a high purchase high to the preparation factory and cash out. The preparation factory is highly covered with the virtual high price of cephalosporin sulfur, so that On the surface, the drug production and circulation links meet the policies and regulations of the "two -vote system", "to evade supervision," said the State Medical Insurance Administration reported.

Earlier was canceled by more provinces and cities

In this regard, the National Medical Insurance Bureau gave measures to require three enterprises such as Tianxin Pharmaceuticals to conduct price rectification of 87 kinds of cephalosporin drugs such as cephalosporin sulfur in the country in accordance with the requirements. Part of the average decrease of more than 50%, and some product regulations have been stopped purchased.

Guangdong Province ordered three companies including Tianxin Pharmaceutical and other related enterprises to comprehensively rectify marketing models to stop relevant illegal operations. In addition, relevant departments are investigating and punishing in accordance with the law for those suspected of disciplinary, illegal, and crimes.

Zhongxin Jingwei noticed that before the notification of the National Medical Insurance Bureau, Baiyunshan Pharmaceutical was canceled in many provinces and cities, including Shanxi Province, Anhui Province, and Guizhou Province.

On June 14, the Shanxi Pharmaceuticals Concentrated Bidding Network issued the "Notice on the Cancellation of 3 Enterprise Platform Purchase Qualifications of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd." Three companies including the General Pharmaceutical General Factory applied for revocation of 89 pharmaceutical regulations for purchasing qualifications on the platform. The bidding enterprise is Jingxiu Pharmaceutical, Baiyunshan Pharmaceutical General Factory and Tianxin Pharmaceutical.

Prior to this, on June 8th, the Shandong Provincial Public Resources Trading Center issued the "Notice on Supplemental Public Notice on Part of the Products". Among them, 22 varieties of Tianxin Pharmaceuticals, including injecting cephalosporin sodium, Ronamycin capsules Wait for the withdrawal.

Why cancel the hanging net? Shanxi Province said "applying in accordance with the enterprise"; Guizhou Province stated that "the declaration of Baiyunshan Pharmaceutical and Tianxin Pharmaceutical"; Anhui Province stated that "according to the requirements of the National Medical Insurance Bureau"; Shandong Province stated that "drug discontinued or duplicate products" stated Shandong Province said that drug discontinuation refers to the production enterprise that has stopped producing the product and currently has no hanging products on other provincial -level drug centralized procurement platforms. Repeated products refer to the products that are repeatedly declared, and the products after the consistency of the quality and efficacy can be revoked before the repetitive products before the evaluation.

Regarding the cost of increasing the drug and drugs notified this time, Bai Yunshan Pharmaceutical has previously withdrawn from the Internet due to the cost of manufacturing costs in the raw medicine. According to the "Notice on the withdrawal of some drugs from the provincial procurement platform" issued by the Heilongjiang Provincial Medical Insurance Bureau in August 2021, the milk nuclear scattered sample boring itching pills of a pharmaceutical industry in Baiyun Mountain cancel the hanging net because of the "in recent years with scientific research The investment in technical reforms has been increasing, and the costs of various manufacturing costs such as raw materials and artificials have risen rapidly. Among them, the price of marking is far from supporting normal production and operation. The subsidiary has been on the "List of Lost Credit"

According to the Guidance Opinions on Establishing Medicine Price and Recruitment Credit Evaluation System, the State Medical Insurance Bureau said that the provincial centralized procurement institutions should implement credit rating on pharmaceutical companies, and according to factors such as the nature, plot, timeliness, influence of the nature of dishonesty, and other factors. The dishonesty situation of pharmaceutical companies in the local bidding and procurement market is a general, medium, severe, and particularly serious level, and dynamically updated every quarter.

In May 2021, Shanghai Sunshine Pharmaceutical Procurement Network issued the "Announcement on the Prosecution Price Price Price of Pharmaceuticals in Shanghai in 2021" (Phase I), which said that The price is higher than the lowest price of five provinces and cities.

In August 2021, the Hunan Provincial Public Resources Service Platform issued the "Notice on the results of Hunan Provincial Pharmaceutical Price and Recruitment of Credit Credit Levels", which rated Tianxin Pharmaceutical as "general".

In March 2022, the Gansu Provincial Medical Insurance Bureau issued the "Result of the Recommendation of the Division of Credit Calculation in Gansu Provincial Procurement Drugs", which stated that Tianxin Pharmaceuticals did not set up regional procurement agreements to withdraw, involving agreed procurement to reduce the amount. Production enterprises have a bad record once.

- END -